Cognitive Pharmaceuticals Ltd.
This article was originally published in Start Up
Executive Summary
Cognitive Pharmaceuticals Ltd. is developing a muscarinic agonist that it believes will replace acetylcholine and so result in immediate improvement in memory for Alzheimer's patients.
You may also be interested in...
AC Immune SA
Swiss-based AC Immune SA is using both an immunological and a small molecule approach to tackling Alzheimer's disease. It hopes that both techniques may lead to compounds that may, by re-balancing the equilibrium between mutant and harmless forms of the protein amyloid beta, halt and perhaps even reverse the progression of the disease.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.